285 related articles for article (PubMed ID: 19916733)
1. Trastuzumab for gastric cancer.
Meza-Junco J; Au HJ; Sawyer MB
Expert Opin Biol Ther; 2009 Dec; 9(12):1543-51. PubMed ID: 19916733
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer.
Lordick F
Future Oncol; 2011 Feb; 7(2):187-99. PubMed ID: 21345138
[TBL] [Abstract][Full Text] [Related]
3. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.
De Vita F; Giuliani F; Silvestris N; Catalano G; Ciardiello F; Orditura M
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S11-5. PubMed ID: 21129604
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab in gastric cancer.
Okines AF; Cunningham D
Eur J Cancer; 2010 Jul; 46(11):1949-59. PubMed ID: 20542421
[TBL] [Abstract][Full Text] [Related]
5. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
Lorenzen S; Lordick F
Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
Barok M; Tanner M; Köninki K; Isola J
Cancer Lett; 2011 Jul; 306(2):171-9. PubMed ID: 21458915
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy for gastric cancer--current status.
Kulig J; Kołodziejczyk P; Kulig P; Legutko J
J Oncol Pharm Pract; 2013 Mar; 19(1):75-81. PubMed ID: 22711713
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T).
Weissinger F; Reymond M; Dumke K; Krüger M
Onkologie; 2011; 34(10):548-51. PubMed ID: 21985855
[TBL] [Abstract][Full Text] [Related]
9. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
Gomez-Martín C; Lopez-Rios F; Aparicio J; Barriuso J; García-Carbonero R; Pazo R; Rivera F; Salgado M; Salud A; Vázquez-Sequeiros E; Lordick F
Cancer Lett; 2014 Aug; 351(1):30-40. PubMed ID: 24943493
[TBL] [Abstract][Full Text] [Related]
10. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
Bang YJ
J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
[TBL] [Abstract][Full Text] [Related]
11. HER2 testing in gastric cancer.
Albarello L; Pecciarini L; Doglioni C
Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
13. [Medical, non-endocrine treatment of metastatic breast cancer--a status].
Lindberg H; Nielsen DL; Kamby C
Ugeskr Laeger; 2007 Apr; 169(17):1556-60. PubMed ID: 17484824
[TBL] [Abstract][Full Text] [Related]
14. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectives.
Bittoni A; Maccaroni E; Scartozzi M; Berardi R; Cascinu S
Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):309-14. PubMed ID: 20496540
[TBL] [Abstract][Full Text] [Related]
16. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care.
Brufsky A
Am J Clin Oncol; 2010 Apr; 33(2):186-95. PubMed ID: 19675448
[TBL] [Abstract][Full Text] [Related]
18. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
